We next tested the ability of NKG2C+KIR2DL1+KIR2DL3- or KIR2DL3+KIR2DL1- ADAPT-NK cells to recognize and eliminate primary AML blasts in PBMC samples derived from patients with distinct HLA-C genotypes. This evidence concerns the gene HLA-C and acute myeloid leukemia.